Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70119 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, 2025. Written by NingNing Zheng and 6 co-authors. Institution: Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou City, China. Major MEDLINE topics: Cardiomyopathy, Hypertrophic, Catheter Ablation. Cited 1 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: This study was sponsored by the Soochow University Cross-Disciplinary Project (No. H211252)..
Abstract (original language)
Background
Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary myocardial disease. Percutaneous endocardial septal radiofrequency ablation (PESA) is an innovative approach for treating HOCM. Consequently, we present the outcomes of the PESA for HOCM.
Methods
This study included 20 patients with HOCM who received PESA. The primary outcomes include the control rate of the left ventricular outflow tract gradient (LVOTG) at rest and following the Valsalva maneuver and changes in New York Heart Association (NYHA) function. Secondary outcomes include changes in interventricular septal thickness (IVST), left ventricular ejection fraction (LVEF), pulmonary artery systolic pressure (PASP), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). In addition, this study assessed the incidence of complications during the perioperative period, the operation time of the PESA, and hospital stays.
Results
After 2 years, the LVOTG for patients decreased 54% at rest and 55% after the Valsalva maneuver. In addition, the NYHA functional index increased from 3.25 ± 0.55 to 1.95 ± 0.88, and 15 patients (75%) achieved NYHA Class I/Ⅱ. The LVEF of patients significantly increased from 63.95 ± 6.29% to 65.75 ± 3.39%, the PASP decreased from 32.50 (31.00, 40.50) mmHg to 23.50 (19.50, 28.50) mmHg, the NT‐proBNP decreased from 388.90 (278.80, 1039.00) ng/mL to 227.4 (121.6, 499.6) ng/mL, and the IVST decreased from 17.20 ± 3.72 mm to 15.80 ± 3.14 mm. Importantly, no patients needed pacemaker treatment. The operative time for the PESA was 186.63 ± 22.47 min, and the median postoperative hospital stay for patients was 10.00 days.
Conclusions
PESA could reduce the LVOTG with the advantages of a low risk of arrhythmias, minimal trauma, rapid postoperative recovery, and shorter hospital stays.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou City, China.
ORCID profiles: NingNing Zheng, Feng Xue, TingBo Jiang
Funding
- This study was sponsored by the Soochow University Cross-Disciplinary Project (No. H211252).
Cite
APA
Zheng, N., Chen, Y., Fu, Y., Xue, F., Zhang, F., Ling, L., & Jiang, T. (2025). Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70119
Vancouver
Zheng N, Chen Y, Fu Y, Xue F, Zhang F, Ling L, et al. Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70119
BibTeX
@article{Zheng2025,
author = {Zheng, NingNing and Chen, YiYuan and Fu, YongBing and Xue, Feng and Zhang, FangFang and Ling, Lin and Jiang, TingBo},
title = {Two‐Year Results of Percutaneous Endocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70119}
}
EUVIMED